Department of Internal Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.
Mayo Clin Proc. 2012 Dec;87(12):1181-8. doi: 10.1016/j.mayocp.2012.08.016.
To derive and validate a risk score for an adverse clinical outcome in adults with meningitis and a negative cerebrospinal fluid (CSF) Gram stain.
We conducted a retrospective study of 567 adults from Houston, Texas, with meningitis evaluated between January 1, 2005, and January 1, 2010. The patients were divided into derivation (N=292) and validation (N=275) cohorts. An adverse clinical outcome was defined as a Glasgow Outcome Scale score of 4 or less.
Of the 567 patients, 62 (11%) had an adverse clinical outcome. A predictive model was created using 3 baseline variables that were independently associated with an adverse clinical outcome (P<.05): age greater than 60 years, abnormal findings on neurologic examination (altered mental status, focal neurologic deficits, or seizures), and CSF glucose level of less than 2.4975 mmol/L (to convert CSF glucose to mmol/L, multiply by 0.05551). The model classified patients into 2 categories of risk for an adverse clinical outcome--derivation sample: low risk, 0.6% and high risk, 32.8%; P<.001; and validation sample: low risk, 0.5% and high risk, 21.1%; P<.001.
Adults with meningitis and a negative CSF Gram stain can be accurately stratified for the risk of an adverse clinical outcome using clinical variables available at presentation.
为患有脑膜炎且脑脊液革兰氏染色阴性的成年人发生不良临床结局的风险建立并验证一个评分系统。
我们对 2005 年 1 月 1 日至 2010 年 1 月 1 日期间在得克萨斯州休斯顿接受评估的 567 名成年人进行了一项回顾性研究。将这些患者分为推导队列(n=292)和验证队列(n=275)。不良临床结局的定义为格拉斯哥结局量表评分 4 或更低。
在 567 名患者中,有 62 名(11%)发生了不良临床结局。使用 3 个与不良临床结局独立相关的基线变量(P<.05)创建了一个预测模型:年龄大于 60 岁、神经系统检查异常(意识状态改变、局灶性神经功能缺损或癫痫发作)和脑脊液葡萄糖水平小于 2.4975 mmol/L(将脑脊液葡萄糖转换为 mmol/L,乘以 0.05551)。该模型将患者分为 2 个不良临床结局风险类别——推导样本:低风险,0.6%和高风险,32.8%;P<.001;验证样本:低风险,0.5%和高风险,21.1%;P<.001。
对于患有脑膜炎且脑脊液革兰氏染色阴性的成年人,可以使用就诊时可用的临床变量准确地对不良临床结局的风险进行分层。